Recurrent ventricular arrhythmias and heart failure induced by osimertinib- a case report
Regular monitoring is required during osimertinib administration, considering the risk of life-threatening cardiac events, such as malignant arrhythmias and heart failure. ISO, with an individual dose and target heart rate, may be beneficial for terminating TdP during poor response to other therapies.
Authors
- Yutong Zhao (ORCID: https://orcid.org/0000-0001-6604-9315)
- Fei She
- Fang Liu (ORCID: https://orcid.org/0000-0003-1121-3004)
- Boda Zhou (ORCID: https://orcid.org/0000-0001-8207-7367)
- Qian Hao (ORCID: https://orcid.org/0000-0001-7397-1535)
- Jing Yang (ORCID: https://orcid.org/0000-0003-2021-3065)
- Jiangying Luo
- Ping Zhang (ORCID: https://orcid.org/0009-0007-1402-0159)
Institutions
- Beijing Tsinghua Chang Gung Hospital (CN)
- Tsinghua University (CN)
Publication Details
- Journal
- Frontiers in Cardiovascular Medicine
- Published
- 2024-08-29
- DOI
- https://doi.org/10.3389/fcvm.2024.1423647
- Citations
- 4
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 1.68